In Situ Fibrin Depot for Vascular Patency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for blocked arteries, such as PTCA and stent placement, often lead to restenosis and require prolonged maintenance of patency to ensure blood flow.
Innovation Solution
The formation of active agent releasing depots in situ, achieved by contacting a composition containing an active agent and a fibrin promoting vessel wall transfer agent with the vessel wall, creating a fibrin matrix that maintains patency over extended periods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If percutaneous transluminal coronary angioplasty (PTCA) or stent placement is performed to treat blocked arteries, then immediate patency is achieved, but restenosis occurs and long-term patency is not maintained
Solution Approach 1:
The patent applies preliminary action by forming a fibrin matrix around the active agent composition before the agent is fully released. This pre-formed matrix acts as a protective framework that maintains patency during the critical early period when the active agent is being delivered, preventing restenosis before the therapeutic agent takes full effect
Solution Approach 2:
The patent uses a fibrin promoting vessel wall transfer agent as an intermediary substance. This agent mediates between the active therapeutic agent and the vessel wall, facilitating the formation of a fibrin matrix that serves as a temporary scaffold. The intermediary agent enables controlled composition transfer while the fibrin matrix maintains structural support and patency
2Reliability
If a composition with high active agent concentration is applied to maintain long-term patency, then therapeutic effectiveness is improved, but the complexity of controlling composition transfer and fibrin matrix formation increases
Solution Approach 1:
The patent applies parameter changes by optimizing the concentration ratio of active agent to fibrin promoting vessel wall transfer agent. By adjusting these compositional parameters, the system achieves effective therapeutic delivery while controlling the complexity of the transfer process. The specific ratio ensures sufficient active agent concentration for effectiveness while maintaining manageable composition characteristics for transfer and matrix formation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively maintains patency of targeted lesions for at least 6 months, and in some cases up to 24 months, reducing the likelihood of restenosis and improving vascular health.
Implementation Method 1
forming an initial fibrin matrix around the composition, wherein the transferred composition can be effective to maintain patency of targeted lesions over a period at least 6 months
Data Source
AI summary
Embodiments herein relate to forming active agent releasing depots in situ for maintaining patency of lesions over extended terms. A method herein of forming an active agent releasing depot in situ for maintaining patency of lesions over extended terms can include contacting a composition with a vessel wall. The composition includes an active agent and a fibrin promoting vessel wall transfer agent, wherein the ratio of active agent to fibrin promoting vessel wall transfer agent (wt./wt.) is at least 5:1. The method can include transferring the composition from a device surface to the vessel wall surface and forming an initial fibrin matrix around the composition. The transferred composition can be effective to maintain patency of targeted lesions over a period at least 6 months. Other embodiments are also included herein.